SLC5A2 and type 2 diabetes mellitus: Our inclusion criteria focused exclusively on RCTs published within the last five years (2019-2024), investigating the efficacy, safety, and long-term outcomes of SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin, either as monotherapy or combination therapy, in patients with T2DM.